Pasithea Therapeutics Corp acquisition of Alpha-5 integrin LLC - Conference Call Transcript
Good morning. My name is Tiago Reis Marques, and I'm the CEO of Pasithea Therapeutics. It is with great pleasure that I'm here today with you to announce the acquisition of Alpha-5 integrin, a preclinical biotech company. Joining me today is our Chairman, Professor Steinman; and our Chief Business Officer, Mathew Lazarus.
Alpha-5 developed a collection of novel monoclonal antibodies with novel IP for the treatment of amyotrophic lateral sclerosis, known as ALS, and other neurological diseases such as multiple sclerosis. We are proud to make our investment in a therapeutic area with huge unmet need.
This target is supported by extensive preclinical and human data providing a novel mechanism of action in the treatment of ALS. We have reproducible data showing survival and motor function efficacy in the SOD mouse model. And we will hear more about the biological rationale in the coming presentation.
These antibodies also show a strong activity profile in animal models of multiple sclerosis, providing Pasithea
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
